Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
propofol hemisuccinate
- Development stage
- Preclinical
- Lead developer
- Epalex
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Administration
- Oral, Inhalation (investigational)
01
Overview
Propofol hemisuccinate is a water-soluble prodrug of propofol, designed to improve the oral and parenteral bioavailability of the parent drug. Upon administration, it is rapidly de-esterified in vivo to release active propofol. Propofol acts primarily as a positive allosteric modulator and agonist at GABA-A receptors in the central nervous system, enhancing inhibitory neurotransmission and producing sedative-hypnotic effects. Propofol also possesses antioxidant properties due to its phenolic structure. Propofol hemisuccinate has been investigated for use in migraine and acute repetitive seizures (including epilepsy), with preclinical evidence supporting antiseizure activity after oral administration. It has also shown efficacy in animal models of autoimmune encephalomyelitis by reducing inflammation and oxidative stress[4][5][8].
- Brand names
- Epalex
- Other names
- succinic acid monopropofol esterbutanedioic acid, 1-(2,6-bis(1-methylethyl)phenyl) ester
02
Targets
GABRR (GABA-A receptor subunit rho)
Beyond the preview
Go deeper on propofol hemisuccinate.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on propofol hemisuccinate.